Dr Akhmal Yusof, CEO of CRM sheds light on the capacity for all stages of clinical research in Malaysia. He discusses the importance of human resources for the country’s research future and explains what makes Malaysia such a worthwhile location to invest in international clinical research.
If we consider the level of sponsored clinical research per capita, Taiwan and Hong Kong are conducting three to four times the level of research as Malaysia, so we have significant scope for growth
Rashidah Ibrahim, executive director of Malaysian Vaccines & Pharmaceuticals (MVP), tells the story of MVP as the sole animal vaccines manufacturer in Malaysia. She also explains how important animal health…
Sherene Azli, CEO of the Malaysia Healthcare Travel Council (MHTC), introduces this unique organization in charge of promoting Malaysia internationally as the ‘Cardiology and Fertility Hub of Asia’ and explains…
Chuwn Leong Ch’ng, CEO of Thunder Print, presents his company’s strategic role within the Malaysian healthcare industry to provide a high-quality packaging services for all type of health products, from…
Writing in the December edition of DIA’s Global Forum magazine, Agnes Ho, Cindy Zen, and Tan Kwee Lan of Boehringer Ingelheim give an overview of the current regulatory framework for…
Writing in the September edition of DIA’s Global Forum magazine, Rosilawati Ahmad of Malaysia’s National Pharmaceutical Regulatory Agency; Tharnkamol Chanprapaph of the Thai FDA; and Samvel Azatyan, Valerio Reggi, and…
Eurasia Group’s Aditya Bhattacharji discusses the relatively modest scope of Malaysia’s recently-launched ‘MYSalam’ scheme; a healthcare programme which aims to provide coverage to the country’s bottom 40 percent of earners.…
See our Cookie Privacy Policy Here